A Study of Contrast-enhanced EBUS in Lung Lesions and Intrathoracic Lymph Nodes (NCT07060378) | Clinical Trial Compass
RecruitingNot Applicable
A Study of Contrast-enhanced EBUS in Lung Lesions and Intrathoracic Lymph Nodes
China250 participantsStarted 2025-07-10
Plain-language summary
Exploring the Clinical Application Value of Contrast Enhancement Features in CE-EBUS Images for the Diagnosis of Pulmonary Lesions and Intrapulmonary Lymph Nodes
Who can participate
Age range18 Years – 90 Years
SexALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion Criteria:
* Age \>18 years oldï¼›
* Enlargement of at least one intrathoracic LN (short diameter \> 1 cm) or central parenchymal lung lesions adjacent to the airway detected on chest CT, or increased fluorodeoxyglucose uptake in at least one intrathoracic lymph node on PET / CT (standardized uptake value \> 2.5)ï¼›
* CP-EBUS-TBNA is required to determine the diagnosis or staging, the patient agreed to undergo CE-EBUS, and there were no contraindications to EBUS-TBNA;
* Patients who have good compliance and sign informed consent.
Exclusion Criteria:
* Patients with known hypersensitivity to ultrasound contrast components;
* Patients with severe pulmonary hypertension (pulmonary artery pressure \> 90 mmHg);
* Patients with angina pectoris, acute coronary syndrome, clinically unstable ischemic heart disease, heart failure, cardiac dysfunction, and cardiac disease with right-to-left shunting;
* Patients with uncontrolled essential hypertension and adults with respiratory distress syndrome;
* Pregnant or lactating womenï¼›
* Patients with contraindications to bronchoscopyï¼›
* Patients with other conditions that, in the opinion of the investigator, make the patient unsuitable for the study.
What they're measuring
1
Diagnostic accuracy of CE-EBUS in the differential diagnosis of benign and malignant intrathoracic lymphadenopathy
Timeframe: 6 month post-procedure
2
Diagnostic accuracy of CE-EBUS in the differential diagnosis of benign and malignant intrapulmonary lesions